Momenta Pharmaceuticals, Inc. (MNTA)

[IB2011]

Ahande,

MNTA has underperformed the market because TEVA poisoned the well. That's why so many analysts are focused on the risk from a TEVA entry into the generic enoxaparin market. This risk is probably overstated and it leads to "Mr. Market" ignoring the other components of MNTA. Try valuing MNTA like any other biotech with a huge patent portfolio and a technology platform that can develop new drugs. Then add several hundred million in cash. I'd stop worrying if I were you and sit back and enjoy the ride over the next 12 months.